Literature DB >> 19811859

A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.

Stefano Guglielmo1, Massimo Bertinaria, Barbara Rolando, Marco Crosetti, Roberta Fruttero, Vanessa Yardley, Simon L Croft, Alberto Gasco.   

Abstract

The synthesis and the study of new amodiaquine derivatives bearing modified lateral basic chains as new agents with both antimalarial and antileishmanial activities are reported. The compounds were tested in vitro against Leishmania donovani MHOM/ET/67/HU3 and 2 strains of Plasmodium falciparum, 3D7 and K1. All the compounds show complex ionisation profiles. At physiological pH the ionised form(s) are in equilibrium with the uncharged form, while at acid pH all the products exist largely as protonated forms. The antiprotozoal profile indicates that all derivatives are endowed with both antimalarial and antileishmanial activity. Interestingly amodiaquine, together with some synthesised derivatives (11, 12, 15, 27, 34), displayed antileishmanial activity in the low micromolar range, although these compounds were also cytotoxic and have a narrow therapeutic window, most of the synthesised compounds proved to be potent antimalarials, a few of them showing a good activity against the chloroquine resistant K1 strain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811859     DOI: 10.1016/j.ejmech.2009.09.012

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Enny Kenangalem; Kim A Piera; David P Fairlie; Emiliana Tjitra; Nicholas M Anstey; Kathy T Andrews; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

2.  A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases().

Authors:  Bryan T Mott; Ken Chih-Chien Cheng; Rajarshi Guha; Valerie P Kommer; David L Williams; Jon J Vermeire; Michael Cappello; David J Maloney; Ganesha Rai; Ajit Jadhav; Anton Simeonov; James Inglese; Gary H Posner; Craig J Thomas
Journal:  Medchemcomm       Date:  2012-12       Impact factor: 3.597

3.  Insights into the structural patterns of the antileishmanial activity of bi- and tricyclic N-heterocycles.

Authors:  Lizzi Herrera; David E Stephens; Abigail D'Avila; Kathryn G George; Hadi Arman; Yu Zhang; George Perry; Ricardo Lleonart; Oleg V Larionov; Patricia L Fernández
Journal:  Org Biomol Chem       Date:  2016-07-04       Impact factor: 3.876

4.  Structural modifications of quinoline-based antimalarial agents: Recent developments.

Authors:  Sandhya Bawa; Suresh Kumar; Sushma Drabu; Rajiv Kumar
Journal:  J Pharm Bioallied Sci       Date:  2010-04

Review 5.  Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review.

Authors:  Arezoo Rafiee Parhizgar; Azar Tahghighi
Journal:  Iran J Med Sci       Date:  2017-03

6.  New trifluoromethyl triazolopyrimidines as anti-Plasmodium falciparum agents.

Authors:  Núbia Boechat; Luiz C S Pinheiro; Thiago S Silva; Anna C C Aguiar; Alcione S Carvalho; Monica M Bastos; Carolina C P Costa; Sergio Pinheiro; Angelo C Pinto; Jorge S Mendonça; Karen D B Dutra; Alessandra L Valverde; Osvaldo A Santos-Filho; Isabela P Ceravolo; Antoniana U Krettli
Journal:  Molecules       Date:  2012-07-10       Impact factor: 4.411

7.  Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites.

Authors:  Ana Carolina C de Sousa; Keletso Maepa; Jill M Combrinck; Timothy J Egan
Journal:  Molecules       Date:  2020-03-29       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.